Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

ClinicalTrials.gov ID: NCT03954743

Public ClinicalTrials.gov record NCT03954743. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Observer-blind, Randomized, Multi-country Study to Assess the Reactogenicity and Safety of the Porcine Circovirus (PCV) Free Liquid Formulation of GSK's Oral Live Attenuated Human Rotavirus (HRV) Vaccine as Compared to the Lyophilized Formulation of the GSK's HRV Vaccine, When Administered as a 2-dose Vaccination in Infants Starting at Age 6-12 Weeks

Study identification

NCT ID
NCT03954743
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,351 participants

Conditions and interventions

Interventions

  • PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine Biological
  • Lyophilized formulation of GSK's oral live attenuated HRV vaccine Biological

Biological

Eligibility (public fields only)

Age range
6 Weeks to 12 Weeks
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 18, 2019
Primary completion
Nov 29, 2020
Completion
Nov 29, 2020
Last update posted
Mar 9, 2022

2019 – 2020

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35235
GSK Investigational Site Colorado Springs Colorado 80922
GSK Investigational Site Louisville Kentucky 40291
GSK Investigational Site Frederick Maryland 21702
GSK Investigational Site Fall River Massachusetts 02721-1735
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Lincoln Nebraska 68504
GSK Investigational Site Lincoln Nebraska 68516
GSK Investigational Site Lincoln Nebraska 68522
GSK Investigational Site East Orange New Jersey 07108
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Cincinnati Ohio 45245
GSK Investigational Site Fairfield Ohio 45014
GSK Investigational Site Corvallis Oregon 97330
GSK Investigational Site Draper Utah 84020
GSK Investigational Site Murray Utah 84107
GSK Investigational Site Orem Utah 84057
GSK Investigational Site South Jordan Utah 84095
GSK Investigational Site Charlottesville Virginia 22902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03954743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2022 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03954743 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →